US12605412B2 - Microbial Compositions for Improving Anticancer Treatment Efficacy
Summary
USPTO granted Patent US12605412B2 to Institut Gustave Roussy, covering microbial compositions for enhancing the efficacy of anticancer treatments. The patent claims compositions combining specific bacterial species (Alistipes senegalensis, Dorea longicatena, Eubacterium siraeum) with immune checkpoint inhibitors and/or tyrosine kinase inhibitors, along with diagnostic methods for assessing patient responsiveness to such treatments.
What changed
USPTO granted Patent US12605412B2 to Institut Gustave Roussy, covering bacterial compositions for use with anticancer immunotherapies and companion diagnostic methods. The patent protects compositions combining Alistipes senegalensis, Dorea longicatena, and Eubacterium siraeum with immune checkpoint inhibitors or tyrosine kinase inhibitors, as well as methods for predicting patient response by measuring relative abundances of specific gut bacterial species.
For parties interested in oncology therapeutics, immune-oncology combinations, or microbiome-based diagnostics, this granted patent establishes IP protection that may affect freedom-to-operate assessments and licensing considerations for microbiome-cancer immunotherapy programs.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and/or tyrosine kinase inhibitors and markers of responsiveness to such treatments
Grant US12605412B2 Kind: B2 Apr 21, 2026
Assignee
Institut Gustave Roussy
Inventors
Laurence Zitvogel, Lisa Derosa
Abstract
The invention pertains to the use of bacteria selected amongst Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum for inducing immunostimulation in a patient in combination with an anti-cancer immunotherapy with an immune check-point inhibitor (ICI) and/or a tyrosine kinase inhibitor (TKI). The invention also relates to methods for assessing the probability that N a patient respond to a treatment with an ICI and/or a TKI, based on measuring the relative abundances of immunotolerant bacterial species (Clostridium hathewayi, Clostridium clostridioforme and Clostridium boltae) and/or immunostimulatory bacterial species CN (Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum) in the patient's gut microbiota.
CPC Classifications
A61K 35/74 A61K 31/404 A61K 31/416 A61K 31/47 A61K 35/741 A61K 45/06 A61K 2035/115 A61P 35/00 C12N 9/22 C12N 15/11 C12N 2310/20 C12N 2800/80 G01N 33/56911
Filing Date
2020-09-29
Application No.
17762263
Claims
16
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.